List your tool

Head to head · 2026

Paige vs Qureight

Pricing, free plans, ratings, features, pros and cons, side by side. Where one comes out ahead, we mark it.

Paige

Digital pathology AI co-pilot from Memorial Sloan Kettering researchers, acquired by Tempus in 2025

4.1Not listed

Visit Paige (opens Paige in a new tab)

Qureight

Imaging biomarkers for lung and heart clinical trials, from a Cambridge deep-learning lab

4.1Not listed

Visit Qureight (opens Qureight in a new tab)

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

  • Lower starting price

    Not comparable

    Not comparable: Paige does not list a price

  • Free plan

    Tie

    Neither has one

  • Higher rating

    Tie

    4.1 against 4.1

  • Same job?

    Yes

    Both are Healthcare AI tools

Side by side

Compared onPaigeQureight
Our rating4.14.1
Starts atNot listedNot listed
Free planNoNo
CategoryHealthcare AIHealthcare AI
PlansSee pricingSee pricing
Key features
  • Paige Alba AI co-pilot for digital pathology tissue-slide analysis
  • Cancer diagnosis, tissue subtyping, and molecular biomarker discovery support
  • Founded in 2017 by researchers from Memorial Sloan Kettering Cancer Center
  • Acquired by Tempus in August 2025, continuing under its own brand
  • Enterprise deployment with dedicated support for hospital and lab pathology teams
  • Deep-learning lung imaging biomarkers Lung8, Air8 and Fibr8
  • Glass8 and Vascul8 for vascular and parenchymal measures
  • Central reads and endpoint discovery for trials
  • Imaging data curation and quality control
  • Built for pulmonary fibrosis, hypertension and bronchiectasis trials
Pros
  • Research pedigree from Memorial Sloan Kettering lends real clinical credibility
  • Tempus backing adds financial resources and precision-medicine data integration
  • Deep oncology pathology specialization outperforms general-purpose medical imaging AI
  • Consistent measurement reduces the variability that costs trial power
  • Named biomarkers rather than a generic imaging claim
  • Focused deeply on respiratory and cardiac disease
Cons
  • Enterprise-only pricing requires a sales conversation before evaluation
  • Now part of a larger company, a real change from its independent-startup years
  • Narrow pathology focus means it's not a fit for non-oncology diagnostic workflows
  • No published pricing; sold to trial sponsors
  • Biomarkers need regulatory acceptance per context of use
  • Narrow therapeutic focus by design
CompanyPaige, founded 2017Qureight Ltd

Prices come from each vendor's pricing page, last checked 20260814. Check the vendor before you buy.

FAQ

Questions people ask

Is Paige better than Qureight?

In our reviews Paige scores 4.1 and Qureight scores 4.1. The better pick depends on the job. Paige: Digital pathology AI co-pilot from Memorial Sloan Kettering researchers, acquired by Tempus in 2025. Qureight: Imaging biomarkers for lung and heart clinical trials, from a Cambridge deep-learning lab.

Which is cheaper, Paige or Qureight?

Paige: see pricing. Qureight: see pricing.

Do Paige and Qureight have free plans?

Neither lists a free plan.

More comparisons